ReviewPurinergic signalling2019
Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future.
Review in Purinergic signalling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Antitumor Efficacy and Immunomodulation of H‑Ferritin Nanocaged Doxorubicin for Triple Negative Breast Cancer.ACS applied nano materials · 2025Article
- Obesity enhances ovarian cancer chemotherapy efficacy through C1q-mediated tumor targeting and immune activation.Journal of nanobiotechnology · 2025Article
- CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma.Journal of nanobiotechnology · 2025Article
- Neutrophil membrane-coated circular RNA nanoparticles for targeted immunotherapy in HER2-positive breast cancer brain metastasis.Cell communication and signaling : CCS · 2025Article
- Chemotherapeutic drug scavenger-based combination therapy toward treating triple-negative breast cancer.Journal of nanobiotechnology · 2025Article
- Tumor microenvironment remodeling with a telomere-targeting agent and its cooperative antitumor effects with a nanovaccine.Journal of nanobiotechnology · 2025Article
- Orchestrated CuJournal of nanobiotechnology · 2025Article
- A novel pH-sensitive nanoparticles encapsulating anti-PD-1 antibody and MDK-siRNA overcome immune checkpoint blockade resistance in HCC via reshaping immunosuppressive TME.Journal of experimental & clinical cancer research : CR · 2025Article
- Innovative approach to the detection of circulating tumor biomarkers: multi-dimensional application of liposome technology.Lipids in health and disease · 2025Review
- Radiotherapy-derived engineered stem cell exosomes improve anti-glioma immunotherapy by promoting the formation of tertiary lymphoid structure and improve the release of type I interferon.Journal of nanobiotechnology · 2025Article
- Multifunctional glycyrrhizic acid-loaded nanoplatform combining ferroptosis induction and HMGB1 blockade for enhanced tumor immunotherapy.Journal of nanobiotechnology · 2025Article
- Oxygen-delivery nanoparticles enhanced immunotherapy efficacy monitored by granzyme B PET imaging in malignant tumors.Journal of nanobiotechnology · 2025Article
- Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma.Discover oncology · 2025Review
- Early elevated IFNα is a key mediator of HIV pathogenesis.Communications medicine · 2024Article
- Unlocking antitumor immunity with adenosine receptor blockers.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Adenosine, Schizophrenia and Cancer: Does the Purinergic System Offer a Pathway to Treatment?International journal of molecular sciences · 2022Review
- Targeting the purinergic pathway in breast cancer and its therapeutic applications.Purinergic signalling · 2021Review
- Article
- Purinergic signaling and tumor microenvironment in cervical Cancer.Purinergic signalling · 2020Review
- Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression.Mediators of inflammation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent years, immunotherapy has produced many unexpected breakthroughs in oncological therapy; however, it still has many deficiencies. For example, the number of patients who are unresponsive to anti-programmed death-ligand 1 (PD-L1), anti-cytotoxic T-like antigen-4 (CTLA4), and anti-programmed death-1 (PD1) therapies cannot be ignored, and the search for an undiscovered immunosuppressive pathway is imminent. Five decades ago, researchers found that activation of the adenosinergic pathway was negatively correlated with prognosis in many cancers. This review describes the entire process of the adenosinergic pathway in the tumor microenvironment and the mechanism of immunosuppression, which promotes tumor metastasis and drug resistance. Additionally, the review explores factors that regulate this pathway, including signaling factors secreted by the tumor microenvironment and certain anti-tumor drugs. Additionally, the combination of adenosinergic pathway inhibitors with chemotherapy, checkpoint blockade therapy, and immune cell-based therapy is summarized. Finally, certain issues regarding treatment via inhibition of this pathway and the use of targeted nanoparticles to reduce adverse reactions in patients are put forward in this review. Graphical Abstract The inhibitors of adenosinergic pathway loaded nanoparticles enter tumor tissue through EPR effect, and inhibit adenosinergic pathway to enhance or restore the effect of immune checkpoint blockade therapy, chemotherapies and immune cell-based therapy. Note: EPR means enhanced penetration and retention, × means blockade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.